News

Clinical Trial

2017-08-07 Announcement

The first clinical trial for candidate botanical new drug BEL-X is a phase I study to determine the drug’s maximum tolerated dose (MTD) and safety for patients with advanced refractory solid malignancies. This study was approved by US FDA in December 2015 and TFDA in May 2017, respectively. IRB approvals were obtained from National Taiwan University Hospital and National Cheng Kung University Hospital in April, 2017. The first patient was successfully recruited on July 7, 2017.

Based on the outcome of the above trial, phase II clinical trials will be designed for treating liver cancer, which plagues the health of Chinese people; lung cancer, the cancer with highest mortality rate; colorectal cancer, the fast growth cancer in recent years; cancer cachexia; and other tumors which do not have satisfactory treatment. These clinical trials will bring BEL-X further to its commercialization to benefit more cancer patients in the world.